These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature. Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992 [TBL] [Abstract][Full Text] [Related]
9. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911 [TBL] [Abstract][Full Text] [Related]
10. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M; J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675 [TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750 [TBL] [Abstract][Full Text] [Related]
12. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies. Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093 [TBL] [Abstract][Full Text] [Related]
13. Status of the neuromyelitis optica spectrum disorder in Latin America. Rivera VM; Hamuy F; Rivas V; Gracia F; Rojas JI; Bichuetti DB; Villa AM; Marques VD; Soto A; Bertado B; Frenk IT; Galleguillos L; Quiñones J; Ramirez DA; Caparó-Zamalloa C; Ciampi E; Lana-Peixoto MA; Rodríguez E; Zarco L; Sinay V; Armas E; Becker J; Benzadón A; Lopez E; Carnero Contentti E; Correa-Diaz EP; Diaz A; Fleitas CV; Playas G; Molina O; Rojas E; Sato D; Soto I; Céspedes JV; Correale J; Barboza A; Monterrey P; Candelario A; Tavolini DR; Parajeles A; Pujol BS; Diaz de la Fe A; Alonso R; Bolaña C; Guzman MK; Carrá A; Gamarra OG; Raggio JV; Rodriguez LC; Ramirez NE; Ordoñez L; Skromne E; Portillo LL; Canabal AP; Weiser R; Sirias V; Calderón RF; Cornejo EA; Hernández M; Quiroz JCD; Garcia LA; Cedeño CO; Martínez J; Abad-Herrera P Mult Scler Relat Disord; 2021 Aug; 53():103083. PubMed ID: 34171682 [TBL] [Abstract][Full Text] [Related]
14. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288 [TBL] [Abstract][Full Text] [Related]
15. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood]. Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886 [No Abstract] [Full Text] [Related]
16. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068 [TBL] [Abstract][Full Text] [Related]
17. The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia. Lalwani CS; Faisal F; Yadav A; Kannoth S; Nambiar V; Gopinath S; Kumar A; Umesh SU; Vincent J; Anoop S; Mathai A; Panicker S Mult Scler Relat Disord; 2023 Jul; 75():104736. PubMed ID: 37126965 [TBL] [Abstract][Full Text] [Related]
18. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827 [TBL] [Abstract][Full Text] [Related]
19. Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD. Paolilo RB; Rimkus CM; da Paz JA; Apostolos-Pereira SL; Callegaro D; Sato DK Mult Scler Relat Disord; 2022 Dec; 68():104215. PubMed ID: 36257150 [TBL] [Abstract][Full Text] [Related]
20. AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature. Spiezia AL; Carotenuto A; Iovino A; Moccia M; Gastaldi M; Iodice R; Tedeschi E; Petracca M; Lavorgna L; d'Ambrosio A; Brescia Morra V; Lanzillo R Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]